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528 The Journal of Thoracic and CardioObjectives: Acute and chronic rejection remain unresolved problems after lung
transplantation, despite heavy multidrug immunosuppression. In turn, the strong
immunosuppression has been responsible for mortality and pervasive morbidity. It
also has been postulated to interdict potential mechanisms of alloengraftment.
Methods: In 48 lung recipients we applied 2 therapeutic principles: (1) recipient
pretreatment with antilymphoid antibody preparations (Thymoglobulin [SangStat,
Fremont, Calif] or Campath [alemtuzumab; manufactured by ILEX Pharmaceuti-
cals, LP, San Antonio, Tex; distributed by Berlex Laboratories, Richmond, Calif])
and (2) minimal posttransplant immunosuppression with tacrolimus monotherapy or
near-monotherapy. Our principal analysis was of the events during the critical first
6 posttransplant months of highest immunologic and infectious disease risk. Results
were compared with those of 28 historical lung recipients treated with daclizumab
induction and triple immunosuppression (tacrolimus-prednisone-azathioprine).
Results: Recipient pretreatment with both antilymphoid preparations allowed the use of
postoperative tacrolimus monotherapy with prevention or control of acute rejection.
Freedom from rejection was significantly greater with Campath than with Thymoglobu-
lin (P  .03) or daclizumab (P  .05). After lymphoid depletion with Thymoglobulin
or Campath, patient and graft survival at 6 months was 90% or greater. Patient and graft
survival after 9 to 24 months is 84.2% in the Thymoglobulin cohort, and after 10 to 12
months, it is 90% in the Campath cohort. There has been a subjective improvement in
quality of life relative to our historical experience.
Conclusion: Our results suggest that improvements in lung transplantation can be
accomplished by altering the timing, dosage, and approach to immunosuppression
in ways that might allow natural mechanisms of alloengraftment and diminish the
magnitude of required maintenance immunosuppression.
Traditional immunosuppressive strategies for organ transplantation have in-volved, from the time of operation, the use of potent multidrug regimens,including a calcineurin inhibitor, high doses of prednisone, and an antime-
tabolite with or without a short course of antilymphoid antibody (induction). Despite
the strong prophylactic immunosuppression, the incidence of acute rejection in the
vascular Surgery ● August 2005
McCurry et al Cardiothoracic Transplantation
TXfirst 6 to 12 months after lung transplantation has remained
high.1 Moreover, complications from the chronic immune
depression and from drug-specific toxicities have been the
rule rather than the exception, with infection-related mor-
tality the most common cause of death in the first 3 years
after transplantation.2 As a result, the 1- and 5-year patient
survivals reported from national and international lung
transplantation registries are 73% to 77% and 42% to 45%,
respectively.2,3
It has also been suggested that excessive early postoper-
ative immunosuppression can potentially subvert postulated
mechanisms of alloengraftment.4 Two therapeutic princi-
ples were applied in 48 lung recipients to avoid this self-
defeating consequence of treatment, beginning in June
2002. First, the lung recipients were infused with a single
large dose of a potent antilymphoid preparation during the
few hours preceding the operation or intraoperatively but
before allograft reperfusion. The pretreatment was either
with a rabbit antithymocyte globulin (Thymoglobulin;
SangStat, Fremont, Calif; n  38) or with the broadly
reacting humanized anti-CD52 monoclonal antibody ale-
mtuzumab (Campath-1H [alemtuzumab], hereafter referred
to as Campath; manufactured by ILEX Pharmaceuticals,
LP, San Antonio, Tex; distributed by Berlex Laboratories,
Richmond, Calif; n  10). Second, the recipients were
treated after transplantation with tacrolimus monotherapy
alone or in combination with very low doses of prednisone
(usually 5 mg/d).
Methods
Recipient and Donor Demographics
All adult patients undergoing single- or double-lung transplanta-
tion or heart-lung transplantation at the University of Pittsburgh
between June 2002 and September 2003 were managed with the
protocol described below, except for 5 recipients in whom there
were logistical difficulties. From June 2002 through June 2003, 37
recipients were pretreated with 4 to 7 mg/kg intravenous Thymo-
globulin; a 38th patient was added in September 2003. Between
June 2003 and August 2003, the second cohort of 10 patients was
pretreated with 30 mg of intravenous Campath instead of Thymo-
globulin. Results are compared with those of 28 unselected pa-
tients who underwent single- or double-lung transplantation or
heart-lung transplantation at the University of Pittsburgh between
December 2001 and June 2002 who were managed with dacli-
zumab (Zenapax) induction, followed by triple-drug immunosup-
pressive therapy.
The characteristics of the patients and donors in the 3 groups
are shown in Table 1. There was no significant difference between
groups for any recipient or donor variable. The indications for
transplantation were broader in the Thymoglobulin-treated and
daclizumab-treated cohorts than in the Campath group (Table 1).
In the Thymoglobulin-treated cohort, other risk factors included 1
(3%) patient with a preexisting, donor-specific, anti-class II anti-
body; 3 (8%) patients with scleroderma; 1 (3%) patient with cystic
fibrosis with Burkholderia gladioli colonization; 2 (5%) patients
The Journal of Thoraciwith sarcoidosis (odds ratio for death at 1 year of 2.03 by Inter-
national Society for Heart and Ling Transplantation [ISHLT]
Registry2); and one recipient of a simultaneous liver.
Immunosuppressive Protocol
The antibody infusions (Thymoglobulin, Campath, or daclizumab)
were initiated as soon as possible after confirmation of the accept-
ability of the donor organs. Thymoglobulin was begun slowly,
with rate escalation every 30 minutes. Campath was infused at a
steady rate over 2 hours. Patients who received Thymoglobulin or
Campath were coadministered 1 g of methylprednisolone to sup-
press cytokine reactions. In all patients 250 mg of methylpred-
nisolone was administered immediately before lung allograft
reperfusion (1 dose for single-lung or heart-lung recipients and 2
doses for double-lung recipients).
Thymoglobulin-treated and Campath-treated patients were
given twice-daily oral tacrolimus (Prograf; Fujisawa Healthcare,
Inc, Deerfield, Ill) beginning on postoperative day 1. Tacrolimus
doses were adjusted to achieve a 12-hour trough level of 12 to
15 ng/mL. All Thymoglobulin-treated patients received 5 mg/d
prednisone beginning on postoperative day 1. Five of the 10
Campath-treated patients were given 5 mg/d (n  4) or 7.5 mg/d
(n  1) prednisone from postoperative day 1 because they were
receiving corticosteroids preoperatively. The other 5 were treated
with tacrolimus only. No patient received an antimetabolite.
For patients who were given daclizumab, the protocol called for
5 doses (1 mg/kg each on day 0, posttransplant day 7, and post-
transplant weeks 2, 4, and 6). These patients also received a
methylprednisolone taper beginning the day of transplantation and
extending over 5 days from 240 mg/d to 40 mg/d, followed by 20
mg of prednisone daily. Twice-daily tacrolimus (target 12-hour
trough level of 15-20 ng/mL) and azathioprine (2-3 mg/kg) were
begun the day of transplantation.
Diagnosis and Treatment of Rejection
Acute rejection was diagnosed by means of histologic examination
of transbronchial or open lung biopsy specimens according to the
revised working formulation for the histologic classification of
pulmonary allograft rejection.5 The specimens were examined and
graded by clinical pathologists according to our standard routine.
Subsequent review of biopsy specimens was carried out at weekly
conferences. Rejection was treated with corticosteroids (ie, 10-day
oral prednisone taper [100 mg to previous baseline] or 1-2 doses of
500-1000 mg of methylprednisolone). In the Thymoglobulin- and
Campath-conditioned patients, grade 2 acute rejection often was
not treated in the absence of deterioration of allograft dysfunction
unless there were histopathologic findings of issue injury. In con-
trast, all grade 2 acute rejection episodes were treated in the
daclizumab cohort.
Higher-grade rejections were treated with 2 to 3 doses of
1000 mg of methylprednisolone, with occasional augmentation
of maintenance steroids or the addition of other baseline agents.
After Campath became available in the autumn of 2002, it was
used to treat steroid-resistant rejection. A few patients were
switched from tacrolimus to cyclosporine because of drug-
specific toxicity.
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Patients receiving Thymoglobulin or Campath pretreatment were
assessed for leukocyte subsets by means of flow cytometry at baseline
(immediately before transplantation) and monitored for recovery at
posttransplant days 1, 7, 14, and 30 and months 3 and 6.
Monitoring of Allograft Function
In all cohorts surveillance spirometry and bronchoscopy with
bronchoalveolar lavage and transbronchial biopsy were per-
formed at 2 and 8 weeks after transplantation and then every 2
to 3 months, as well as when clinically indicated.
Infection Monitoring and Prophylaxis
Infection prophylaxis against cytomegalovirus (CMV) in Thy-
moglobulin- and Campath-treated patients consisted of 450 to
900 mg/d valganciclovir (Valcyte; Roche Laboratories, Nutley,
NJ) for 6 months. For prophylaxis against fungus and yeast, 6
mg/kg voriconazole (Vfend; Pfizer, New York, NY) was ad-
ministered intravenously every 12 hours for 2 doses, followed
by 200 mg twice daily for 4 months. Pneumocystis carinii
prophylaxis was with one trimethoprim/sulfamethoxazole
TABLE 1. Demographics of lung transplant recipients in th
Thymoglobulin
Number 38
Average age (y) 47  13 (25-68)
Sex (M/F) 17/21
Underlying disease
COPD 12 (37%)
CF 8 (21%)
IPF 5 (13%)
A1A deficiency 5 (13%)
Scleroderma/crest 3 (8%)
Sarcoidosis 2 (5%)
PPH 1 (3%)
Pulmonary fibrosis 1 (3%)
EG 1 (3%)
OB/Retx
Other
Type of transplantation
Single 17 (45%)
Double 20 (53%)
Heart, double lung
Double lung  liver 1 (2%)
Living lung donor lobar
CMV (D/R) 13/38 (34%)
EBV (D/R) 2/38 (5%)
HLA mismatch 4.5  1.3
PRA  10% 1/38 (3%)
Ischemia time (min) 345 101
Donor age (y) 35 15 (14-63)
COPD, Chronic obstructive pulmonary disease; CF, cystic fibrosis; IPF, idiop
pulmonary hypertension; EG, eosinophilic granuloma; OB/Retx, obliterative
PRA, panel reactive antibody.(TMP/sulfa) single strength tablet 3 times per week.
530 The Journal of Thoracic and Cardiovascular Surgery ● AuguDaclizumab-treated patients received valganciclovir and TMP/
sulfa as described but received 3 months of fluconazole (Diflucan,
Pfizer) prophylaxis in lieu of voriconazole.
Spaced Reduction of Tacrolimus
In 17 Thymoglobulin-pretreated recipients who were 6 months
or more after transplantation, an effort was made to reduce
tacrolimus dosing to 4 times a week or 3 times per week. The
decisions were made either as a search for the lowest level of
treatment consistent with stable graft function in response to
low-level nephrotoxicity or because of concern about smolder-
ing infection or incipient posttransplant lymphoproliferative
disease.
Informed Consent and Data Compilation
Because the efficacy and safety of the immunosuppressive strategy
had been demonstrated with other kinds of organ transplanta-
tion,6,7 the treatment regimen was deemed with the agreement of
the University of Pittsburgh Institutional Review Board to be
within the boundaries of standard therapy. The protocol was re-
viewed and authorized by the Presbyterian University Hospital
ymoglobulin, Campath, and daclizumab groups
Campath Daclizumab P value
10 28
 11 (37-70) 49  14 (22-65) NS
7/3 15/13 NS
NS
2 (20%) 8 (29%)
5 (18%)
4 (40%) 8 (29%)
1 (3%)
1 (10%) 2 (7%)
1 (3%)
3 (30%) 1 (3%)
2 (7%)
NS
5 (50%) 12 (43%)
4 (40%) 15 (54%)
1 (10%)
2/10 (20%) 7/28 (25%) NS
0/10 1/28 (3%) NS
5.2  0.8 5.2  0.9 NS
1/10 (10%) 2/28 (7%) NS
354 85 329 82 NS
39 16 (11-62) 35  15 NS
pulmonary fibrosis; A1A deficiency, 1-antitrypsin deficiency; PPH, primary
hiolitis retransplantation; CMV, cytomegalovirus; EBV, Epstein-Barr virus;e Th
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In addition, all patients provided informed consent for enrollment
under an institutional review board–approved protocol for studies
not routinely performed in our conventional practice and for re-
porting of outcomes. Data were collected in a prospective manner.
Data integrity and safety and efficacy monitoring were ensured by
means of establishment of a formal weekly review of cases.
Because Campath cases were compiled recently, the comparisons
between the therapeutic antibodies are limited to 6 months.
Statistical Analysis
The 2 statistic was used to determine the significance of nominal
variables. Continuous variables were compared by either a Student
t test or a Kruskal-Wallis test. All P values reported are 2 tailed.
Survival and freedom-from-rejection analysis was determined by
Kaplan-Meier actuarial analysis, and differences were compared
with the log-rank test. Values are reported as means  SD.
Results
Tolerability of Pretreatment Protocol
The antibody infusions were begun as soon as possible after
determination of the acceptability of donor organs. Frequently,
this preceded initiation of general anesthesia. All infusions
were completed before graft reperfusion. Thymoglobulin was
infused over an average of 225 68 minutes (range, 120-433
minutes), whereas Campath was infused over 2 hours. Both
agents were generally well tolerated. In one patient with ob-
structive lung disease, significant bronchospasm began before
Figure 1. The effect of Thymoglobulin and Campath on
The dashed line represents the value of 100 cells/Lstarting Thymoglobulin and continued afterward. Thymo-
The Journal of Thoraciglobulin was transiently stopped and later resumed at a slower
rate, allowing almost a full dose (4 mg/kg) to be administered
before allograft reperfusion. Another patient who received
Thymoglobulin had significant hyperthermia, resulting in
slowing of the rate of infusion.
Immune Cell Reconstitution
Pretreatment with 4 to 7 mg/kg Thymoglobulin resulted in
profound depletion of T cells (CD3) by postoperative day 1.
T-cell counts remained less than baseline values for 3 months,
with a gradual return toward normal levels by 3 to 6 months
after transplantation (Figure 1, A). The CD8 population recov-
ered more rapidly than the CD4 population. Although CD8 cell
counts returned to baseline by 1 to 3 months after transplan-
tation, CD4 cell counts remained at less than baseline value for
up to 6 months (Figure 1, B-C). This pattern resulted in an
inverted CD4/CD8 ratio that persisted up to 6 months after
transplantation. B cells were not depleted by Thymoglobulin
(Figure 1, D).
The level of T-cell depletion achieved was significantly
greater and more sustained with Campath than with Thy-
moglobulin (Figure 1, A) and included CD8 and CD4 phe-
notypes (Figure 1, B-C). CD4 (helper) cells were the most
profoundly affected. The mean value for CD3 cell counts
depicted in Figure 1, A, at 6 months was due to high cell
counts in 2 patients. The remainder of patients had cell
ocyte subsets and their recovery after transplantation.
text).16 Values are expressed as means  SD.leuk
(seecounts that were 290 cells/L or less.
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pleted with Campath but returned to normal levels by 3
months (Figure 1, D).
Rejection Episodes
The incidence and overall burden of acute rejection was
compared in patients who survived at least 2 weeks after
transplantation (37/38 Thymoglobulin-treated patients,
10/10 Campath-treated patients, and 26/28 daclizumab-
treated patients). The percentage of patients with at least
one episode of grade 2 or greater acute rejection in the
first 6 posttransplant months was no different between the
Thymoglobulin- and daclizumab-treated cohorts (25/37
[68%] vs 17/26 [65%], P  not significant [NS]). In
contrast, the Campath cohort had significantly fewer pa-
tients with rejection (2/10 [20%]; P  .008 vs Thymo-
globulin and P  .02 vs daclizumab). Similarly, there
was no difference in the percentage of patients with
high-grade rejection (grade 3) between the Thymo-
globulin- and daclizumab-treated cohorts (16/37 [43%]
vs 12/26 [46%], P  NS), whereas no Campath-condi-
tioned patients had high-grade rejection (P  .01 vs
Thymoglobulin and P  .01 vs daclizumab). Figure 2
shows the Kaplan-Meier plot of freedom from greater
than or equal to grade 2 rejection, demonstrating the
lower incidence of rejection in the Campath cohort.
In addition, in those patients who experienced rejec-
tion, the number of rejection episodes was fewer in the
Campath cohort compared with the Thymoglobulin and
Figure 2. Kaplan-Meier plot of freedom from graddaclizumab cohorts. The average number of grade 2 or
532 The Journal of Thoracic and Cardiovascular Surgery ● Augugreater episodes of rejection per patient was 1.45 in the
Thymoglobulin cohort and 1.15 in the daclizumab cohort
(P  NS) but was significantly less in Campath-treated
patients (0.2 episodes per patient [ie, a single episode of
grade 2 rejection in 2 patients], P  .007 vs Thymo-
globulin and P  .03 vs daclizumab). Neither Campath-
preconditioned patient was treated with augmented im-
munosuppression for the grade 2 rejection. The frequency
of high-grade rejection episodes was similarly no differ-
ent between Thymoglobulin- and daclizumab-treated pa-
tients (0.81 vs 0.57 episodes per patient, respectively; P
 NS) but was significantly less in Campath-treated
patients (0 episodes, P  .02 vs Thymoglobulin and P 
.032 vs daclizumab). No patients in any group had his-
topathologic evidence of obliterative bronchiolitis during
the first 6 months.
Survival
Six-month survival was not statistically different between the
groups. Although survival in the Thymoglobulin and Campath
groups was greater than our previous 3-year experience, the
difference did not reach statistical significance (Figure 3).
Six-month survival in the Thymoglobulin-treated cohort was
97% (37/38). The only death during this period occurred on
postoperative day 9 because of the sequelae of ischemia-
reperfusion injury. One patient required early retransplantation
(postoperative day 54) for allograft dysfunction after transplan-
tation for sarcoidosis. The patient survived. Thus, graft survival
r greater rejection. ACR, Acute cellular rejection.e 2 oat 6 months was 95% (36/38).
st 2005
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90% (9/10). The only death occurred on postoperative day
23 in a 70-year-old recipient of a double-lung transplant (for
emphysema) after an apneic episode on the ward.
Six-month survival in the daclizumab group was 89%
(25/28).
Pulmonary Function
The average forced expiratory volume in 1 second (FEV1)
in the Thymoglobulin-treated cohort at 6 months was 70%
 19%, whereas that in the Campath-treated cohort was
80%  27% (P  NS). One single-lung recipient in the
Thymoglobulin-pretreated group reached a peak FEV1 at 2
months after transplantation, with a subsequent decrease in
values. Although transbronchial and open lung biopsies
have not revealed any evidence of pathologic obliterative
bronchiolitis, the FEV1 values meet bronchiolitis obliterans
syndrome 2 criteria.8 This patient had preexisting donor-
specific anti-HLA class II antibody (Table 1). No Campath-
treated patients met bronchiolitis obliterans syndrome
criteria.
Infection
There was no significant difference in infection rates among
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Figure 3. Kaplein-Meier actuarial survival curves for t
group of patients receiving lung transplants at the Univ
2002. Although pretreatment with either Thymoglobulin
text, resulted in a greater than 10% difference in 1-yea
and the historical group, the difference did not reach
sample size.the 3 groups, although there was a trend toward less CMV-
The Journal of Thoraciinduced disease in the Campath cohort. Eighteen percent
(5/28) of patients in the daclizumab group, compared with
8% (3/38) in the Thymoglobulin group and 0% in the
Campath group, had histologically proved CMV-induced
disease (P  .23). There were 3 cases of Nocardia species
(one each of Nocardia Nova, Nocardia farcinica, and
Nocardia asteroides complex) recorded in patients receiv-
ing Thymoglobulin pretreatment, whereas none occurred in
the other groups (P  .19).
Survival After 6 Months
The potential follow-up for the 38 Thymoglobulin-
pretreated recipients is now 9 to 23 months. Although 37
patients were alive at 6 months, 3 more deaths occurred by
1 year (2 caused by sepsis and 1 caused by posttransplant
lymphoproliferative disease), and 2 additional deaths oc-
curred after 13 and 16 months (viral influenza and chronic
rejection, respectively). Thus, the 1-year actuarial survival
is 86%. Thirty-two (84.2%) of the original 38 patients are
alive, with a mean follow-up of 17.1  4.0 months. Except
for the death at 3 weeks of a 70-year-old emphysematous
recipient, all of the other Campath-pretreated patients are
alive, with a mean follow-up of 10.5  4.4 months (range,
e (years)
2 3
Thymoglobulin cohort
Campath cohort
Lung transplant recipients 7/99-6/02 
(n=140)
ymoglobulin and Campath cohorts, as well as for the
y of Pittsburgh Medical Center from July 1999 to June
mpath with resultant management, as described in the
vival between the Thymoglobulin and Campath groups
tical significance. This is likely because of the smalll Tim
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statis9-17 months).
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In 16 of the 32 surviving patients pretreated with Thymo-
globulin, an attempt was made to reduce tacrolimus doses to
3 or 4 times a week. Five of the 16 patients remain stable on
spaced dosing after a mean period of 8.5  2.8 months
(range, 6-12 months). Weaning was discontinued in the
other 11 patients because of decreases in pulmonary func-
tion or because of histopathologic evidence of destructive
immunity on biopsy. Despite augmentation of immunosup-
pression, full restoration of baseline function was achieved
in only 3 of these patients. In contrast, the other 16 surviv-
ing recipients of the Thymoglobulin cohort who have been
maintained on daily (twice a day or once a day dosing)
tacrolimus monotherapy or near-monotherapy have had no
deterioration in pulmonary function after a mean follow-up
of 14.6  3.7 months.
Discussion
There are obvious limitations to this study. Because it was
a phase I-II study rather than a prospective randomized trial,
definitive comparisons could not be made with contempo-
raneous (or, in our report, historical) control patients treated
with conventional multiple drug immunosuppression. In
addition, follow-ups are still short, particularly for the co-
hort of Campath-pretreated recipients. Nevertheless, it is
noteworthy that our 6-month patient survival (97% and 90%
in the Thymoglobulin and Campath cohorts, respectively) is
competitive with the 89% 6-month survival with triple-drug
immunosuppression in our immediately preceding experi-
ence and the benchmark 79% of the ISHLT registry.2 More-
over, current survival is 84.2% of our Thymoglobulin-
pretreated recipients with follow-ups of 9 to 23 months and
has remained at 90% since postoperative week 3 in the
Campath-pretreated patients who are now 9 to 17 months
after transplantation. In addition, no further deaths have
occurred as additional patients (40) have received trans-
plants with Campath preconditioning. These results were
achieved without an increased risk of infection and, in fact,
with a trend toward less CMV-induced disease in an uns-
elected series of patients who had a large representation of
high-risk factors.
Both Thymoglobulin and Campath are potent lymphoid-
depleting agents. Thymoglobulin9,10 has properties similar
to the original polyclonal antilymphoid globulins that were
introduced clinically nearly 40 years ago, and the more
T-cell specific muromonab (OKT3). Campath was devel-
oped by Hale and Waldmann11 and first used for kidney
transplantation by Calne and colleagues.12 In accord with
reports by Knechtle,13 Kirk,14 and their associates, our data
demonstrate that Campath has a more profound and pro-
longed lymphoid depletion than Thymoglobulin, including
depression of the B-lymphocyte and natural killer lineages
without causing major decreases in platelet counts. The
534 The Journal of Thoracic and Cardiovascular Surgery ● AuguCampath effect lasted for 6 months compared with the few
weeks of Thymoglobulin. Because the extent and duration
of T-cell depletion is thought to correlate with the avoidance
of rejection,15 including that of thoracic organs,16 the lower
rate of rejection in the Campath cohort relative to the
antilymphoid globulin group was not surprising.
Moreover, the acute rejections were less severe in the
patients pretreated with Campath. The incidence of grade 2
or higher acute rejection in the Thymoglobulin-treated pa-
tients was 66%, although the treated acute rejection rate was
47%. The incidence of rejection was similar to that seen
with standard triple immunosuppression without use of an-
tibody induction,17 as well as in some series in which
antilymphoid globulins were administered postoperatively.1
In contrast, only 2 of the 10 Campath-pretreated patients
had 1 episode each of grade 2 acute rejection (neither
treated), and no patients had grade 3 rejection or higher.
These patients were treated with steroid boluses or a short
course of another agent but otherwise managed throughout
with low maintenance immunosuppression. Five of the 10
recipients treated with Campath never were administered
anything but tacrolimus, whereas the other 5 also were
given 5 mg/d or less prednisone, usually because the pa-
tients previously had received chronic steroid therapy.
The timing of the lymphoid depletion in our patient
deserves particular emphasis. The theory underlying our
treatment strategy is that the seminal mechanism of organ
alloengraftment is passenger leukocyte–driven clonal
exhaustion-deletion,18 an immune activation-dependent
mechanism that can be variably eroded by heavy prophy-
lactic postoperative immunosuppression.4 Lymphoid deple-
tion before exposure to donor alloantigen was designed to
avoid this pitfall, reduce the anticipated donor-specific re-
sponse into a more deletable range, and allow the safe use
of minimum posttransplant immunosuppression. Thus our
hypothesis was (and is) that organ engraftment is a state of
variable partial tolerance that can be made more complete
by modifying the timing and dosage of immunosuppression.
Our view of organ engraftment and its relation to ac-
quired tolerance has been controversial. A large body of
historical and recent work has led to alternative hypotheses
to explain organ engraftment, acquired tolerance, or
both.19,20 These theories emphasize the importance of im-
munoregulatory T cells, other changes in the host immune
response, or both that can downregulate alloimmune or
autoimmune responses. In addition to T-cell immunoregu-
lation, subsets of other special cells, changes in the host
cytokine profile, or the development of enhancing antibod-
ies might play a role. In an attempt to foster these mecha-
nisms, lymphoid depletion has been done elsewhere at and
after the time of transplantation. In recent trials Campath (or
Thymoglobulin) was administered in 2 doses: the first in-
traoperatively and the second a few days later. Preliminary
st 2005
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TXresults, especially after renal transplantation, have been
encouraging.12-14
Our strategy of lymphoid depletion before, rather than at
or after, transplantation also has been shown to be effective
for kidney, liver, and other kinds of organ transplanta-
tion.6,7,21 Implementing this regimen in a clinical setting of
thoracic organ transplantation entailed 2 concerns. The first
question was whether the use of minimalist posttransplant
immunosuppression might result in an unacceptable loss of
allografts to uncontrollable acute rejection. In the experi-
ence reported herein, the risk of short-term graft loss to
acute rejection was no greater than with conventional im-
munosuppression in either the Thymoglobulin- or Campath-
pretreated recipients.
The second question concerned the extent to which daily
minimal maintenance immunosuppression could be sus-
tained after recovery from the lymphoid depletion or re-
duced further, without the penalty of breakthrough acute
rejection or indolent chronic rejection. Studies in mice by
Wu and colleagues22 have raised the possibility that recov-
ery from lymphoid depletion (homeostatic proliferation)
might be associated with heightened long-term immune
reactivity. The adverse consequences could include vigor-
ous later rejection that could become evident only with long
follow-up. This issue can be tentatively addressed with
observations in the Thymoglobulin-pretreated recipients, 32
of whom survive after 17.1  4.0 months (range, 9-23
months).
Fifteen of the 32 patients have been maintained on ta-
crolimus monotherapy for 14.6  3.7 months (range, 9-22
months), with no deterioration of graft function. An addi-
tional patient who had been maintained on twice-daily ta-
crolimus had a late rejection episode (11 months) and re-
quired the addition of mycophenolate mofetil after
treatment with steroids. In 16 others in whom spaced re-
duction of tacrolimus was attempted, this was tolerated by
only 5 patients. Therefore we have concluded that attempts
at spaced reduction of tacrolimus should not be made unless
there is a specific reason to do so (eg, calcineurin inhibitor–
related renal dysfunction or an ongoing infection). A similar
approach is being taken in the Campath-pretreated patients.
We emphasize, however, that much longer follow-ups will
be needed before the threat posed by chronic rejection can
be fully evaluated.
Randomized trials comparing the results with the dif-
ferent timing of antilymphoid antibody treatment, as well
as comparisons of the lymphoid-depleting strategies with
conventional immunosuppression, could lead to better
care of lung recipients. In addition to analyses of clinical
outcomes, detailed immune monitoring in such trials
might help resolve disputes about the mechanisms of
engraftment. Finally, the observations with lung trans-
plantation are expected to be generalizable to other or-
The Journal of Thoracigans, including the heart. We have pretreated 3 heart-
lung recipients with Campath (one included in the current
report) and a recent heart-only recipient. All 4 patients
have been free of rejection on tacrolimus monotherapy.
We thank Terry L. Mangan for secretarial assistance and all
members of the University of Pittsburgh Lung and Heart-Lung
Transplantation Program for their dedication to patient care.
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Discussion
Professor Bruce Rosengard (Cambridge, United Kingdom). I
would like to first congratulate Dr McCurry and his colleagues
at Pittsburgh for the courage to apply the pioneering work of my
colleague, Professor Sir Roy Calne, to lung transplantation. As
we all know, many of the early obstacles to lung transplantation
have been overcome, but as you so rightly pointed out, the
long-term outcomes caused by obliterative bronchiolitis remain
a plague of the lung transplant recipient. To the extent that
obliterative bronchiolitis is caused by an immune response,
there is no patient group in transplantation that is more in need
of better immunosuppressive therapy.
Sir Roy’s concept of Prope or almost tolerance has now been
applied to several hundred liver or kidney recipients worldwide
and is presently undergoing phase III testing to establish effi-
cacy in comparison with conventional triple-drug immunosup-
pression. Indeed, of Sir Roy’s original 29 kidney patients
treated with Campath and cyclosporine monotherapy, 26 remain
on low-dose cyclosporine monotherapy, and the other 3 have
had azathioprine and steroids added back. All patients at more
than 5 years’ follow-up now are doing very well clinically, with
virtually normal renal function.
If the majority of lung recipients are able to be treated with
long-term monotherapy after an intense lymphocyte cytoreduc-
tion, this will be a major clinical advance because side effects
and long-term complications will be reduced, even though the
approach does not achieve true tolerance. I have 3 questions for
the authors.
In your article you attribute your clinical observations to
clonal deletion or exhaustion of alloreactive T-cell clones;
however, other clinical investigators have shown persistence of
alloreactive clones after Campath induction followed by tacroli-
mus monotherapy. Do you have evidence for either clonal
deletion or exhaustion, or is it more likely that your protocol
allows for the emergence of regulatory T cells, which mute the
immune response?
Dr McCurry. Thank you very much, Bruce, for your kind
comments, and I would also like to take the opportunity from a
personal standpoint to thank you for your contributions and
leadership in thoracic transplantation and personally for some
support that you provided to me.
Your question is a very good one. Our paradigm has been
that of clonal exhaustion deletion, meaning that passenger leu-
kocytes migrate from the organ and go through a process with
diminished initial alloimmune responses of clonal proliferation
and ultimate exhaustion. This is based on historical work at our
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kidneys and livers. We have little data in the lung transplant
population to demonstrate or suggest that this is definitely the
mechanism by which this is occurring.
We have done some early in vitro responses, and we do have
2 patients who have diminished, not absent, responses, but who
are hyporesponsive by mixed leukocyte reaction in vitro; how-
ever, there are certainly many other patients who maintain in
vitro alloreactivity. In addition, we do have 2 patients who
show a diminished frequency of donor-specific reactive T cells,
as determined by means of limiting dilution assay, but again,
many do not. Therefore, I think what we see is that for some
reason, many of these patients are able to be maintained on
low-dose monotherapy.
The issue of whether we are inducing a regulatory T cell is
a very good question also. As I am sure you well know, Stewart
Knechtle and Alan Kirk have used Campath induction in kidney
recipients, and I believe that both groups have recently reported
the demonstration or a suggestion of development of a regula-
tory T cell in patients who have been treated with Campath who
are now more than a year out from their transplantations.
Most of our Campath-treated patients are relatively early after
transplantation at this point, but this is certainly an area that we are
interested in and an area that we are beginning to look at, looking
for both the CD4, CD25 regulatory cell and the CD8 popu-
lation that the Columbia group has identified. In addition, we have
also been looking for FOXP3, as well, which, as you know, is the
marker of perhaps a tolerant phenotype.
Professor Rosengard. Second, there is emerging evidence
that T cells that repopulate a recipient after intense lymphocyte
cytoreduction acquire the phenotype of memory or immunized
cells, even in the absence of alloantigen. Do you think that this
will limit the long-term efficacy of this approach because mem-
ory T cells are notoriously resistant to immunosuppressive
therapy?
Dr McCurry. Another very good question and something
that we are concerned about. I think most of this work demon-
strating repopulation with a memory phenotype, as has been
done by yourself, as well as Larry Turk and the group at Emory,
which we have certainly read with interest, is an area that we
are just now beginning to look at in our patients. We really do
not have any data, but we are trying to look at the phenotype of
the cells that do repopulate after both Thymoglobulin and
Campath treatment. I do not know. It is hard to say. Certainly
a mouse is not a man, and I think that Sir Roy Calne’s data
perhaps would argue that it is not a concern in human trans-
plantation, although certainly a kidney is not a lung either.
Professor Rosengard. Finally, I am happy to see that you
are planning to do a prospective randomized study. I was going
to ask you, given the fact that hundreds of patients have been
studied with phase I protocols in kidney and liver transplanta-
tion, why was it that you chose to do a phase I study in lung
recipients as opposed to going for the full Monty?
Dr McCurry. I think for several reasons. One is, obviously,
as this group well knows, that lungs are difficult, and the early
outcomes after lung transplantation have been notoriously dif-
ficult. We thought it best to obtain some safety data as an initial
foray into this at a single center. I think it is also true that in
st 2005
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either from an immunologic or a safety standpoint a lot of the
work that has been done in abdominal transplantation. A recent
application of this, that is, the use of rapamycin after trials in
kidneys, resulted in some bad outcomes in lung transplant
recipients with bronchial dehiscence. Therefore we believed it
was best to pursue a safety trial initially at our center, and then,
on the basis of these data, we hope to proceed to a multicenter
randomized trial.
Dr Thomas M. Egan (Chapel Hill, NC). Dr McCurry, con-
gratulations on some outstanding results. My question does not
relate to the immunologic aspect so much as a dramatic lack of
problems with reperfusion injury. Most early mortality in lung
transplantation relates to graft failure, and at least in your Campath
group, it appears that you have avoided that. Is that just blind luck,
or are you actually seeing a reduction in reperfusion injury as
evidenced by ventilation duration, et cetera?
Dr McCurry. Thanks very much, Tom. It is an area that we
also have been interested in, and I am sure part of it is blind
luck, but there are some data, as I am sure you are well aware,
that at least Thymoglobulin, the polyclonal agents, decrease
ischemia-reperfusion injury in kidney transplantation, and our
anecdotal results thus far with Campath have been that the early
graft function is quite good. It is something that we are inter-
ested in at least from a clinical standpoint, comparing with
some retrospective cohorts.
Dr Egan. Does that imply that the T cell is involved in that
reperfusion injury?
Dr McCurry. There are certainly experimental data in animals
to suggest that, and it might very well be.
Dr Alec Patterson (St Louis, Mo). Ken, that was an excellent
presentation, very nicely delivered. If I understood or interpreted
your slides correctly, the 1-year early survival really was not much
different than what is reported in most experienced centers. There-
fore although this strategy might have some relevance to bronchi-
olitis obliterans syndrome in later follow-up, I would have thought
that we would see a reduction in early postoperative complications.
Can you comment on that?
Dr McCurry. Thank you, Alec, and thank you and your
group for your contributions and your leadership. We only have
Thymoglobulin-treated patients who are 1 year out, and our
1-year survival in that patient population is 87%, so it compares
favorably with ISHLT data. But as you suggest, many experi-
enced centers report 1-year survival of greater than 80%.
Certainly during the early course of using Thymoglobulin in
this patient population, we went through a learning curve, and
although we had one death in that group in the first 6 months—
therefore we had 37 of 38 survivors in the Thymoglobulin group at
6 months—we did have another 3 deaths in the subsequent 6
The Journal of Thoracimonths, and if I recall correctly, I believe that 2 of those deaths
were due to sepsis and a third was due to a viral-related process,
adult respiratory distress syndrome. It was a learning curve
through that process.
I believe our results right now with Campath have been quite
good, and we do have about 37 patients who are doing well, and
I anticipate we will have a very good 1-year survival in that patient
population. Again, only time will tell.
Dr Duane R. Davis, Jr (Durham, NC). I rise to congratulate
you for having the courage to try to change the paradigm of
immunosuppression. Dr Alan Kirk, in his experience with Cam-
path in kidney transplant recipients, noted an acute rejection pro-
cess that was dominated histologically by macrophage and mono-
cytes. You have demonstrated that your patients treated with
Campath have no T cells. What are the cells that are infiltrating the
graft? As a secondary comment, what is the difference between
peripheral and central depletion between Thymoglobulin and
Campath?
Peripheral depletion tends to be pretty good with both. How-
ever, central compartment depletion, which is probably going to be
much more important in terms of being able to approach a tolero-
genic or at least a minimal immunosuppression strategy, probably
is significantly better with Campath than with Thymoglobulin.
Dr McCurry. Thank you, Duane. Those are both very
interesting questions. I think, as you suggest, when Alan pub-
lished his data, of course he used Campath induction, I believe,
if I recall correctly, 2 doses, about 40 mg, 50 mg, perhaps, with
no baseline immunosuppression afterward. What we have typ-
ically seen in the Campath-treated patients is a bit of an early
alloimmune response that has been a typical mononuclear T-
cell infiltrate.
Now we have not done the immunostains and the typing with
immunohistochemistry that Alan did in his study, but certainly the
appearance of the grade 2 cases that we have seen look like other
grade 2 cases that we have seen with Campath. Now that might be
because perhaps we are not depleting as much as Alan was because
we are giving a smaller dose, a single 30-mg dose as opposed to
multiple doses up to 40 or 50 mg, but we really have not appre-
ciated a difference from a histologic standpoint.
Your second question about central depletion is a very good
question. Our paradigm has been to try to get all of the Cam-
path, or whatever agent we are using, in before allograft reper-
fusion. Again, we are using a smaller dose of Campath than
most of the abdominal groups have; I believe Alan has used up
to 60 mg in his patient population, and Stewart perhaps used a
similar dosing. Therefore, ideally we are depleting centrally.
We do not have data to demonstrate that, but certainly from a
peripheral standpoint, it takes a long time to reconstitute the
CD8 population, particularly the CD4 population.
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